NEW YORK, March 28, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Stemline Therapeutics, Inc. (“Stemline”) (NASDAQ:STML) (1) pursuant and/or traceable to Stemline's secondary public offering on or about January 20, 2017; and/or (2) on the open market between January 6, 2017 and February 1, 2017, inclusive. You are hereby notified that Levi & Korsinsky has commenced the class action Braswell v. Stemline Therapeutics, et al. (Case No. 1:17-cv-00853) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra/stemline-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the class period the Company made materially false and/or misleading statements and/or failed to disclose that: (i) a patient had died in the BPDCN Trial from capillary leak syndrome immediately prior to the Company’s stock offering despite consistently stating that capillary leak syndrome was a potential side-effect of SL-401; and (ii) SL-401’s safety profile did not remain predictable and manageable over increasing treatment duration, drug exposure, and patient experience as represented by the Defendants.
Take Action: if you suffered a loss in Stemline Therapeutics you have until April 4, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 



